apixaban + dabigatran + edoxaban + aspirin + clopidogrel

This entry refers to the set of antithrombotic agents—comprising the direct oral anticoagulants (DOACs) apixaban, dabigatran, and edoxaban, and the antiplatelet agents aspirin and clopidogrel—evaluated in the MOSES clinical trial (2024-517600-11-01). Sponsored by Universitaetsspital Basel, the MOSES trial investigates whether biomarker-guided (MR-proANP) secondary stroke prevention using DOACs reduces recurrent stroke compared with standard antiplatelet therapy in patients with recent acute ischemic stroke and no documented atrial fibrillation. The DOAC components function as selective inhibitors of either Factor Xa (apixaban, edoxaban) or thrombin (dabigatran), while the antiplatelet components inhibit platelet aggregation via cyclooxygenase-1 (aspirin) or the P2Y12 receptor (clopidogrel). The trial aims to optimize secondary prevention strategies by identifying patients who may benefit more from anticoagulation than from standard antiplatelet therapy based on elevated mid-regional pro-atrial natriuretic peptide (MR-proANP) levels.

Other names

Acetylsalicylic acidDabigatran etexilateClopidogrel bisulfateDOACs vs antiplatelets